Personalis (NASDAQ:PSNL) Stock Price Up 11.3% – Time to Buy?

Personalis, Inc. (NASDAQ:PSNL)’s stock price was up 11.3% during trading on Thursday . The stock traded as high as $11.39 and last traded at $11.9980. Approximately 339,639 shares were traded during trading, a decline of 81% from the average daily volume of 1,800,092 shares. The stock had previously closed at $10.78.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PSNL shares. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, May 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Morgan Stanley cut their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Needham & Company LLC boosted their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, BTIG Research cut their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Trading Up 14.2%

The stock has a market capitalization of $1.29 billion, a P/E ratio of -12.02 and a beta of 2.28. The stock’s fifty day moving average price is $7.09 and its two-hundred day moving average price is $8.16.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. As a group, analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Insider Activity at Personalis

In other Personalis news, CEO Christopher M. Hall sold 80,091 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $11.02, for a total transaction of $882,602.82. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $2,600,565.72. The trade was a 25.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 38,799 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $11.58, for a total transaction of $449,292.42. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,302,486.14. The trade was a 16.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 138,799 shares of company stock valued at $1,551,292 in the last quarter. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Aberdeen Group plc increased its position in Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the period. Oracle Investment Management Inc. bought a new position in Personalis in the third quarter worth $1,496,000. ARK Investment Management LLC raised its holdings in Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares in the last quarter. D.A. Davidson & CO. bought a new position in Personalis in the fourth quarter worth $1,158,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Personalis in the fourth quarter worth $2,308,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.